Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07755176

Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors

This study will evaluate patient-reported outcomes before and after percutaneous ablation of desmoid tumors. Adult participants undergoing ablation for desmoid tumor will complete surveys pre and post procedure to assess symptom burden, impact on daily life, early post-procedural pain and recovery, concomitant treatments, and radiological response following ablation.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Desmoid Tumor Aggressive Fibromatoses Desmoid Tumors Fibroma Neoplasms Neoplasms by Histologic Type Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms, Fibrous Tissue

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients undergoing ablation for desmoid tumor.

Exclusion criteria

  • Declines to participate in research.

Treatment and study plan

Desmoid tumor ablation

Procedure

Percutaneous ablation of desmoid tumor

Primary outcomes

  1. Change in desmoid tumor symptom severity following ablation

    Time frame: Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation

    Desmoid tumor symptom severity following ablation will be measured using the GODDESS© Desmoid Tumor Symptom Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores indicate greater symptom burden.

  2. Change in desmoid tumor impact following ablation

    Time frame: Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation

    Desmoid tumor impact following ablation will be measured using the GODDESS© Desmoid Impact Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms on patients' daily lives and functioning. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores are expected to indicate greater disease-related impact.

  3. Change in post-procedural pain score

    Time frame: Baseline; 7 days; 1 month and 3 months post-ablation

    The pain score is calculated from a 2 question self-report survey asking recipients to rate pain on a scale of 1-10. Higher scores indicate worse pain.

Secondary outcomes

  1. Radiological response following ablation

    Time frame: Through 24 months post-ablation

    Radiologic assessment of desmoid tumor response on follow-up imaging, including tumor response characteristics as available in the medical record.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 10, 2026
Registry last updated
Aug 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.